Member Info for itsallamess

Soluble clever 1

Good question he is keeping quite aboutATM to test it before fully understood

Spending H2 forecast to be less than H1

Dosing and frequency in mantins trial

Not far from optimal dosing to go to regulators to move on to next phase.

One cohort they give 1 dose a week and it's working well

1 saves life is calculated at 50,000 pound so times that by who bex can save gives the value of the company

Questions.
Surrounded by possible partners, discussions are on going but not gonna rush into anything but it's looking exciting

Looking at options for the next funding if it's better to get a partner or go it alone

He feels that the regulators will be happy with all their data to move on with further trials

He feels that the regulators will be happy with all their data to move on with further trials

Bexmab is being used to treat leukemia

Markku seemed very excited with this. That's why they got the funding for this

Biomarker data is above 90 which is excellent for predicting clinical benefits of bex

Over 80 is considered good

So they a very good chance of working out who bex will work on which is very important for phase 3 trials

I've submitted your questions.. let's see if they are answered :)

When you register they send a email link. That email link opens up on a countdown page that as I write this would be to start at 12 but it also says it starts at 11pm

I'm logged on waiting and see what happens

Let's see what Marku says shortly.

I'm sure he is well aware of the share price and if they want to tempt more investment he will have to show that their investment will ho up rather than down.

Even Timo investment of millions is underwater.

You now have "Compelling 12-month survival data with 100% survival among checkpoint refractory melanoma and cholangiocarcinoma patients", would it not be better to focus all bex energy on these to get to market to generate income then focus on the other cohorts?

Anyone who has invested in the past 2 years have seen their investment decrease in size: how does he feel about it? What will faron be doing to rectify this?

Cwebb, why don't you put the question about ssv to marku this morning? Nows your opportunity.

"there is potential for Phase II expansion and to include a first line triplet therapy of bexmarilimab, azacitidine and venetoclax in newly diagnosed acute myeloid leukemia (AML) patients who are not able to tolerate chemotherapy"

Azacitidine and Venetoclax are commercialized by AbbVie and Genentech, a member of the Roche Group.

The strongest survival benefit was seen in checkpoint refractory melanoma and cholangiocarcinoma, where 12-month survival was 100% among patients who benefited from bexmarilimab treatment and 6% for patients who did not benefit from treatment.

However looking back, we never got anything the past 2 times.

7pm RNS it is?

Thursday is half year results
Friday is the presentation thing by maija

Possible RNS for Thursday morning. On the twitter link ot actually says

"Could #bexmarilimab help cancer patients that have no other options? And if so, when? Maija Hollmén might have some news at BioCity Symposium 26 August."